SEC Form 4 · accession 0001209191-17-009602
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas Teti
Director
Period of report
Feb 8, 2017
Accepted (ET)
Feb 10, 2017 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 10 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Option (Right to Buy)F3 | $7.12 | Feb 8, 2017 | A | 40,000 | A | Feb 8, 2017 | Feb 8, 2027 | Common Stock | 40,000 | 40,000 | D |
| Director Option (right to buy)F1,F2 | $47,008.50 | holding | — | — | — | Apr 27, 2007 | Apr 27, 2017 | Common Stock | 4 | 4 | D |
| Director Option (right to buy)F1,F2 | $27,730.50 | holding | — | — | — | May 6, 2008 | May 6, 2018 | Common Stock | 1 | 1 | D |
| Director Option (right to buy)F1,F2 | $12,159.00 | holding | — | — | — | May 5, 2009 | May 5, 2019 | Common Stock | 1 | 1 | D |
| Director Option (right to buy)F1,F2 | $14,490.00 | holding | — | — | — | May 28, 2009 | May 28, 2019 | Common Stock | 23 | 23 | D |
| Director Option (right to buy)F1,F2 | $3,402.00 | holding | — | — | — | Feb 10, 2010 | Feb 10, 2020 | Common Stock | 11 | 11 | D |
| Director Option (right to buy)F1,F2 | $2,646.00 | holding | — | — | — | May 6, 2010 | May 6, 2020 | Common Stock | 1 | 1 | D |
| Director Option (right to buy)F1,F2 | $2,761.50 | holding | — | — | — | May 5, 2011 | May 5, 2021 | Common Stock | 9 | 9 | D |
| Director Option (right to buy)F1,F2 | $2,908.50 | holding | — | — | — | May 9, 2012 | May 9, 2022 | Common Stock | 9 | 9 | D |
| Director Option (right to buy)F1,F2 | $924.00 | holding | — | — | — | May 8, 2013 | May 8, 2023 | Common Stock | 9 | 9 | D |
| Director Option (right to buy)F1,F3 | $1,932.00 | holding | — | — | — | May 7, 2014 | May 7, 2024 | Common Stock | 23 | 23 | D |
| Director Option (right to buy)F1,F3 | $1,176.00 | holding | — | — | — | May 6, 2015 | May 6, 2025 | Common Stock | 23 | 23 | D |
| Director Option (right to buy)F1,F4 | $1,176.00 | holding | — | — | — | Jun 6, 2015 | May 6, 2025 | Common Stock | 23 | 23 | D |
| Director Option (Right to Buy)F1,F3 | $52.50 | holding | — | — | — | May 4, 2016 | May 4, 2026 | Common Stock | 42 | 42 | D |
Explanation of responses
- F1On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- F2Fully vested.
- F3Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
- F4Vests in cumulative installments of 1/12th per month beginning the date shown.
Remarks
EX 24: Teti Power of Attorney Attached THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.